Oncorx Pharmaceuticals is an early-stage pharmaceutical company developing high-affinity drugs that selectively target the P-glycoprotein/CD44/Integrin β1 protein complex that is overexpressed on the surface of therapy-resistant tumors. Activation of α5β1 integrin plays an important role in regulating cytoskeletal reorganization, F-actin polarization, the epithelial-to-mesenchymal transition, anchorage-independent tumor cell growth, and tumor cell apoptosis. Currently available cancer therapies are targeted to primary, untransformed tumor cells and are not effective in treating resistant transformed tumors that have entirely different cell surface receptor targets and actin cytoskeletal organization. Oncorx is developing oncology drugs that not only target resistant tumors, but also effectively penetrate the blood-brain-barrier to reach the tumor sanctuary in the brain. Numerous clinical studies have demonstrated that patient survival is strongly dependent upon the time it takes for tumors to reach the brain from their primary site in the body.
View Top Employees from Oncorx Pharmaceuticals, Inc.Website | https://oncorxpharmaceuticals.com |
Revenue | $4 million |
Employees | 1 (1 on RocketReach) |
Founded | 2014 |
Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Oncorx Pharmaceuticals, Inc. employee's phone or email?
The Oncorx Pharmaceuticals, Inc. annual revenue was $4 million in 2024.
Donald Barbeau is the President and Chief Scientific Officer of Oncorx Pharmaceuticals, Inc..
1 people are employed at Oncorx Pharmaceuticals, Inc..
The NAICS codes for Oncorx Pharmaceuticals, Inc. are [32541, 32, 3254, 325].
The SIC codes for Oncorx Pharmaceuticals, Inc. are [28, 283].